HGS Stock Dips After It Ends Hepatitis C Test
158244
Human Genome Sciences' stock price plunged more than 40 percent yesterday, after the company announced it would abandon higher-dose tests of its hepatitis C drug because an independent monitoring group expressed concerns about lung-related side effects.
220564
H&amp;R Block&#39;s (HRB:NYSE - news - research) low-multiple shares cheapened Wednesday as investors tried to digest its explanation for a wide first-quarter earnings miss.
95023
The U.S. Dow Jones Industrial average  declined on Thursday after drug maker Merck & Co.MRK.N  recalled its widely sold Vioxx painkiller and its stock sunk 27  percent.
132494
US stocks fell as setbacks for drugmakers, including a study showing Pfizer Inc.&#39;s Celebrex painkiller increased the risk of heart attacks, sent health-care shares tumbling.
577581
Stocks fell after building materials maker USG Corp.  raised concerns about the housing slump, while chemical company DuPont Co.  put a damper on the earnings reporting season with results that missed estimates.
414602
Stock falls on news treatment failed a mid-stage trial, company will cease developing drug. NEW YORK  - AtheroGenics Inc.
65715
Hepatitis C results propel shares up.
691333
The company updates investors on the progress of its lead drug for hepatitis C.
390028
NEW YORK  -The Dow and the S&P recovered from their earlier drops to trade flat, after U.N. officials said there was no danger from vials of chemicals found in a locked box in a United Nations building in New York.
370237
Schering-Plough's positive study results send shares of Vertex down.
374358
Wall Street stocks closed mixed Friday as investors concerned about economic health after the government report showed a drop in gross domestic product growth.
97474
YESTERDAY Close $32.94 Change +$0.63 52-WEEK High $45.38 Low $25.61 Biotechnology company Vertex Pharmaceuticals Inc. said its loss widened in the third quarter, as it invested more in its hepatitis C drug candidate and relied less on collaborative funding.
768203
NEW YORK - Stocks were mixed Thursday after Merck & Co. said it would be forced to remove its best-selling Vioxx arthritis drug from the market due to serious health risks...
677746
NEW YORK - Wall Street closed out a dismal third quarter with a mixed performance Thursday after Merck & Co. said it would be forced to remove its best-selling Vioxx arthritis drug from the market...
353033
Shares plunge after company says its vein graft treatment failed to show benefit in late-stage test. CHICAGO  - Biotechnology company Corgentech Inc.
764330
U.S. stock futures pointed to a  slightly lower open on Tuesday as investors take a step back  after last week's three-day rally, with shares of drug maker  Merck & Co. MRK.N under pressure as regulators step up  investigations into the company's withdrawal of its pain  reliever, Vioxx.
619072
Leading shares closed absolutely flat today after a pretty volatile session, taking a breather following sharp falls over the week with Wall Street registering a moderate rally helped by a narrowing of the US trade gap and soothing comments from a Fed official, dealers said.